Overview of Drug Product Development

Narayan, Padma

doi:10.1002/0471141755.ph0703s55

Cited by 5 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug products, also commonly known in the pharmaceutical industry as formulations or "dosage forms" are used for administering the active pharmaceutical ingredient (API) for purposes of assessing safety in preclinical models, human clinical trials, and for routine clinical/commercial use sooner or later. Narayan's research [6] discussed the approaches for creating small-molecule API dosage forms; it will come soon near the future from pre-formulation to commercial manufacturing.…”

Section: Prospect Of Genetically Engineered Pharmaceutics In the Futurementioning

confidence: 99%

Development and Prospect of Genetically Engineered Pharmaceutics

Huang

White

Shi

et al. 2013

AMR

View full text Add to dashboard Cite

With the rapid development of modern biology and technology, Genetically Engineered Pharmaceutics has become the most important field in modern medicinal industry. Currently, we have taken concern that the Genetically Engineered Pharmaceutics has been a subject of research. As advanced genetically engineered technology, genetic therapy, the point mutation techniques, DNA shuffling, RNA interference (RNAi) technology, the bioinformatics for genome and proteome analyses, the high throughput screening technology, etc. can be applied in the treatment of cancer, and other targeted therapies. A great deal of advanced technologies accelerates the development of genetically engineered pharmaceutics, and plays a key role in genetically engineered pharmaceutics. With the advances in genetically engineered pharmaceutics, we look forward to finding more new drugs, such as the high-value peptides, small functional molecular groups, proteins, especially antibodies, vaccines, enzymes, and therapeutic peptides. These developments continue to secure greater health outcomes of human being at all aspects in the long run. In this article, the development and prospect of Genetically Engineered Pharmaceutics are reviewed, and furthermore, the potential development and huge prospects are also presented.

show abstract

Section: Prospect Of Genetically Engineered Pharmaceutics In the Futurementioning

confidence: 99%

Development and Prospect of Genetically Engineered Pharmaceutics

Huang

White

Shi

et al. 2013

AMR

View full text Add to dashboard Cite

show abstract

“…Moreover, excipients perform multiple functions, besides completing the formulation volume, such as improving bioavailability, administration and acceptance of the treatment by the patient (Loftsson, 2015;Narayan, 2011;Wening and Breitkreutz, 2011). Another fundamental characteristic of excipients is their pharmacological and toxicological inactivity that allows them to be used at high doses (Abrantes et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

EXCI-CEST: Exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging

Longo

Moustaghfir

Zerbo

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Chemical Exchange Saturation Transfer (CEST) approach is a novel tool within magnetic resonance imaging (MRI) that allows visualization of molecules possessing exchangeable protons with water. Many molecules, employed as excipients for the formulation of finished drug products, are endowed with hydroxyl, amine or amide protons, thus can be exploitable as MRI-CEST contrast agents. Their high safety profiles allow them to be injected at very high doses. Here we investigated the MRI-CEST properties of several excipients (ascorbic acid, sucrose, N-acetyl-d-glucosamine, meglumine and 2-pyrrolidone) and tested them as tumor-detecting agents in two different murine tumor models (breast and melanoma cancers). All the investigated molecules showed remarkable CEST contrast upon i.v. administration in the range 1-3ppm according to the type of mobile proton groups. A marked increase of CEST contrast was observed in tumor regions up to 30min post injection. The combination of marked tumor contrast enhancement and lack of toxicity make these molecules potential candidates for the diagnosis of tumors within the MRI-CEST approach.

show abstract